Superpower peptides available for pre-order. Get first access.
Not FDA-approved
Digestive & weight
What is the difference between oral and injectable BPC-157?
Oral and injectable BPC-157 have each been studied in animals and early human research. See what research has measured for each route and form.
Quick answer
Oral and injectable BPC-157 differ in what research has measured for each route. No FDA-approved drug contains BPC-157, and it has no established labeled route. Injected BPC-157 had a half-life under 30 minutes in rats and dogs. Oral BPC-157 has been studied for healing in rats. Oral absorption has not yet been measured. Three small human studies, 30 people in all, used injection or infusion. Registered trials cover subcutaneous injection, tablets, and gummies. WADA bans BPC-157 at all times.
- Published
- November 4, 2026
- Last updated
- November 4, 2026
Oral and injectable BPC-157 differ in what has been studied
Oral and injectable BPC-157 (Body Protection Compound-157) differ in what research has measured for each route. Most BPC-157 findings come from laboratory and animal studies. The first human studies1 have now been published. Absorption data for injected BPC-1572 come from rats and dogs. Oral research has focused on healing in rats.
BPC-157 is a synthetic peptide derived from a stomach protein fragment3. No FDA-approved drug contains BPC-1572, and no USP or NF quality standard exists for it.
Without a labeled route, each route's record comes from research, beginning with injected BPC-157 in animals.
How has injected BPC-157 been studied?
Injected BPC-157 has been studied in rats and dogs through four injection routes.
- Subcutaneous (under the skin): seven days of dosing in rats4, measuring brain serotonin synthesis
- Intramuscular (into muscle): BPC-157 free base2 in rats and beagle dogs, tracking absorption and clearance5
- Intraperitoneal (into the abdominal cavity): rats with cut Achilles tendons, measuring tendon strength and repair6
- Intravenous (into a vein): a single dose in rats and dogs in the same study
Injected BPC-157 had an elimination half-life under 30 minutes5 in rats and dogs. Intramuscular bioavailability, the share reaching the bloodstream, averaged about 14%-19% in rats and 45%-51% in dogs5.
How has oral BPC-157 been studied?
Oral BPC-157 has been studied in rats given the peptide in their drinking water7. FDA's review identified no animal studies tracking oral absorption2.
Oral BPC-157 was one of three routes tested in a rat study of cut knee ligaments. Ligament repair measures improved with each route, oral included. The study reported each route separately, without ranking them.
In laboratory testing, BPC-157 resisted breakdown in gastric juice2. Absorption by mouth also depends on the intestine, the gut wall, and the liver. Those steps have no published data yet3.
Oral BPC-157 has also been studied in rats with colon injuries, where drinking-water dosing preceded repair of colon lesions8. That result reflects direct contact between BPC-157 and the rat gut.
What has human research used?
Human BPC-157 research has used injection or infusion in three published studies with 30 people1. Registered trials also cover subcutaneous and oral routes.
- Knee joint injection: a retrospective review of 16 people1
- Bladder injection: a retrospective pilot of 12 people with interstitial cystitis (chronic bladder pain)
- Intravenous infusion: a two-adult safety pilot9 that reported no side effects
- Rectal enema: two early trials reported as meeting abstracts, where BPC-157 was mostly undetectable in blood2
- Subcutaneous injection: a rotator cuff repair pilot trial10, not yet recruiting
- By mouth: a Phase 1 tablet trial11 planned for 42 people, and a completed single-group gummy study in 40 people12, neither with results posted
No human study has yet compared the two routes head to head. Each form's own details matter.
What to check in each form
Each BPC-157 form needs its own checks, since route and chemical form decide which research applies. FDA evaluated BPC-157 free base and BPC-157 acetate as separate bulk drug substances2. The clinical studies FDA reviewed do not clearly identify either form2.
| Form | What to check |
| Injection | Concentration, vial strength, sterility, storage, and who prepared it |
| Oral capsule or tablet | The exact form and salt on the label (free base, acetate, or another salt), and what stability and absorption evidence covers that form |
| Nasal or topical | Whether the cited research used that route, since FDA found no human absorption data for nasal or transdermal2 BPC-157 |
Oral BPC-157 is sold in the US as supplement capsules2 and tablets. Research or experience with one route does not automatically describe another.
WADA prohibits BPC-157 at all times as a non-approved substance13 (class S0), in every form and route. Athletes subject to drug testing can face sanctions for BPC-157 use and should check current WADA and league rules.
Getting BPC-157 in 2026
Superpower will offer BPC-157 formulated in FDA-registered facilities in the US, backed by third-party lab testing, and distributed from US-licensed pharmacies. A licensed clinician will assess whether it fits each person's health care. The Superpower peptide waitlist is open now.
BPC-157 lacks FDA approval as a drug. Under an interim policy announced in October 2026, the Department of Health and Human Services does not intend to take enforcement action14 against state-licensed pharmacies compounding BPC-157 while the 503A Bulks List (the list of ingredients pharmacies may use in compounding) is finalized. That policy extends to six peptides, BPC-157 included15, and its conditions include ingredients from FDA-registered facilities and a patient-specific prescription. It came after a July 2026 FDA advisory committee voted to recommend BPC-157 for the list16; rulemaking is ongoing.